Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Large Growth in Short Interest

Xenetic Biosciences Inc (NASDAQ:XBIO) saw a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 108,700 shares, an increase of 84.2% from the October 31st total of 59,000 shares. Based on an average daily volume of 633,000 shares, the short-interest ratio is currently 0.2 days. Approximately 2.4% of the company’s shares are sold short.

Separately, ValuEngine raised shares of Xenetic Biosciences from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd.

Shares of XBIO stock opened at $1.17 on Wednesday. The company’s fifty day simple moving average is $1.22 and its 200-day simple moving average is $2.53. Xenetic Biosciences has a 52 week low of $0.93 and a 52 week high of $42.84.

An institutional investor recently raised its position in Xenetic Biosciences stock. Morgan Stanley grew its holdings in Xenetic Biosciences Inc (NASDAQ:XBIO) by 1,050.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 36,082 shares of the company’s stock after acquiring an additional 32,945 shares during the period. Morgan Stanley owned about 4.14% of Xenetic Biosciences worth $406,000 as of its most recent SEC filing. Institutional investors own 12.07% of the company’s stock.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.

Featured Article: How is an ETF different from a mutual fund?

Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.